ITMCTR2100004838招募中1 期
Pilot randomised double-blind placebo-controlled trials of Wuzhuyu Decoction in relieving chemotherapy-induced nausea and vomiting of breast cancer
Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 100(—)
- 性别
- Female
入选标准
- •1. Patients signed informed consent and voluntarily joined the study;
- •2. Breast cancer was confirmed by pathology or Histocytology;
- •3. Excluding chemotherapy contraindications, breast cancer patients who plan to receive intravenous chemotherapy drugs;
- •4. At any time during the current chemotherapy regimen, although there were antiemetic drugs consistent with the guidelines, there was significant CINV. The specific criteria were: nausea and vomiting or the need for more than one supplementary antiemetic drug, and / or >= moderate nausea on the 5-level scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe);
- •5. The patient's ECoG status was 0, 1 or 2;
- •6. The researchers determined that the patient could be treated with Wuzhuyu decoction;
- •7. Aged >=18 years;
- •8. Life expectancy greater than or equal to 4 months;
- •9. Willing and able to comply with all research requirements, including treatment, time and nature of assessment required, including diary, quality of life, urine test and any statutory blood test.
排除标准
- •1. Allergic to traditional Chinese Medicine;
- •2. The researcher judged other conditions not suitable for inclusion in the study;
- •3. Symptomatic primary or secondary central nervous system malignancies;
- •4. Symptomatic gastrointestinal obstruction;
- •5. Disease related nausea or vomiting, need daily antiemetic treatment;
- •6. History of epilepsy or recurrent seizures;
- •7. Schizophrenia, other psychosis, severe personality disorder, except depression associated with underlying illness;
- •8. Patients who are pregnant, breast-feeding or lack of contraception. Women with fertility must have a negative pregnancy test 7 days before registration;
- •9. Patients who participated in other clinical trials in recent 3 months.
研究者
相似试验
已完成
不适用
A pilot double-blind randomised controlled trial comparing two physiotherapy interventions to treat femoroacetabular impingement.Physical Medicine / Rehabilitation - PhysiotherapyMusculoskeletal - Other muscular and skeletal disordersFemoroacetabular impingementACTRN12615001218583a Trobe University, La Trobe Sport and Exercise Medicine Research Centre40
进行中(未招募)
1 期
Trial of oxytocin for the treatment of emotional withdrawal symptoms and for relapse prevention in abstinent heroin dependent individualsOpioid dependence. The study will be investigating the efficacy of Syntocinon (oxytocin) on treating the withdrawal symptoms and cravings that opioid (e.g. almost always heroin) dependent individuals experience following detoxification.MedDRA version: 20.0 Level: LLT Classification code 10057379 Term: Addiction relapse System Organ Class: 100000004873MedDRA version: 20.0 Level: LLT Classification code 10001126 Term: Addiction any drug System Organ Class: 100000004873EUCTR2014-002708-26-GBniversity of Surrey3
已完成
不适用
A pilot study of D-cycloserine-augmented cognitive behavioural therapy (CBT) with exposure therapy in adolescents with obsessive-compulsive disorder (OCD)Mental and Behavioural DisordersObsessive-compulsive disorderISRCTN70977225Institute of Psychiatry, Kings College London (UK)24
进行中(未招募)
1 期
A randomised double-blind placebo-controlled pilot study of D-cycloserine-augmented exposure therapy in adolescents with obsessive-compulsive disorderEUCTR2008-006947-38-GBKing's College London (Institute of Pyschiatry)24
进行中(未招募)
不适用
Pilot double blind randomised placebo controlled crossover trial of Hyoscine for the treatment of Clozapine induced nocturnal sialorrhoea. - Reducing Excess Salivation Trial (REST)Sialorrhoea in patients treated with clozapine.MedDRA version: 12.0Level: LLTClassification code 10059812Term: SialorrhoeaEUCTR2009-016300-23-GBKing's College London12
